Thomas Harding Biography and Net Worth

Insider of Clovis Oncology

Dr. Thomas Fuglsang Harding has served as our Executive Vice President since March 2021 and Chief Scientific Officer since October 2019. Dr. Harding joined Clovis in June 2012 as a Senior Director of Preclinical Research & Translational Medicine, and since joining, he was promoted through multiple levels, before taking the role of CSO. Dr. Harding has 20 years of oncology drug discovery and development experience and previously served in research leadership positions at FivePrime Therapeutics and Cell Genesys, Inc. Dr. Harding received a Ph.D. and completed post-doctoral training at the University of Bristol, U.K. in Molecular Neuroscience, in addition to a BSc in Microbiology.

What is Thomas Harding's net worth?: The estimated net worth of Thomas Harding is at least $0.00 as of October 3rd, 2022. Dr. Harding owns 3,683 shares of Clovis Oncology stock worth more than $0 as of December 4th. This net worth evaluation does not reflect any other investments that Dr. Harding may own. Learn More about Thomas Harding's net worth.
How do I contact Thomas Harding?: The corporate mailing address for Dr. Harding and other Clovis Oncology executives is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. Clovis Oncology can also be reached via phone at 303-625-5000 and via email at [email protected]. Learn More on Thomas Harding's contact information.
Has Thomas Harding been buying or selling shares of Clovis Oncology?: Thomas Harding has not been actively trading shares of Clovis Oncology in the last ninety days. Learn More on Thomas Harding's trading history.
Who are Clovis Oncology's active insiders?: Clovis Oncology's insider roster includes Paul Gross (Insider), Thomas Harding (Insider), Gillian Ivers-Read (Insider), and Lindsey Rolfe (Insider). Learn More on Clovis Oncology's active insiders.

Thomas Harding Insider Trading History at Clovis Oncology

Thomas Harding Buying and Selling Activity at Clovis Oncology

Clovis Oncology Company Overview

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Today's Range

Now: N/A

50 Day Range

MA: $0.43

$0.08

$1.09

2 Week Range

Now: N/A

Volume

1,155,888 shs

Average Volume

8,875,886 shs

Market Capitalization

$11.60 million

P/E Ratio

N/A

Dividend Yield